Drug Interactions between oritavancin and tasimelteon
This report displays the potential drug interactions for the following 2 drugs:
- oritavancin
- tasimelteon
Interactions between your drugs
tasimelteon oritavancin
Applies to: tasimelteon and oritavancin
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes. When tasimelteon was administered after 11 days of treatment with the potent CYP450 inducer rifampin 600 mg/day, tasimelteon systemic exposure (AUC) decreased by approximately 90% compared to tasimelteon administered alone. No data are available for use with other, less potent inducers.
MANAGEMENT: The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4. Alternative treatments may be required if an interaction is suspected.
Drug and food interactions
tasimelteon food
Applies to: tasimelteon
Food can delay the absorption of tasimelteon, which may increase the amount of time it takes for the medication to work. You should take tasimelteon without food at the same time each night before going to bed. If you are a smoker, there is a possibility that tasimelteon may not work as well for you due to reduced blood levels of the medication in smokers compared to nonsmokers. You should avoid or limit the use of alcohol while being treated with tasimelteon. It can increase some of the side effects including dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. Talk to your doctor or pharmacist if you have any questions or concerns.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.